The cumulative burden at age 30 years and rate of cumulative burden growth is variable across cancer subtypes and organ systems. Figure shows distribution of cumulative burden by age among childhood cancer survivors of specific pediatric cancer subtypes and community controls participating in the SJLIFE cohort study. This finding contrasts with the cumulative burden in matched community controls, who experienced 9.2 chronic health conditions, 2.3 of which were severe/disabling, life threatening, or fatal (see Figure 1).Įnlarge Figure 1. By age 50 years, survivors in this cohort experienced an average of 17.1 chronic health conditions, 4.7 of which were severe/disabling, life threatening, or fatal. Jude Life (SJLIFE) cohort study aimed to describe the cumulative burden of cancer therapy using the cumulative burden metric, which incorporates multiple health conditions and recurrent events into a single metric that takes into account competing risks. 20% to 80% of survivors experience severe or life-threatening complications during adulthood.60% to more than 90% of survivors develop one or more chronic health conditions.Multi-institutional and population-based studies have shown excess risk of hospital-related morbidity among childhood and young adult cancer survivors compared with age- and sex-matched controls, with some evidence that this risk is disproportionately high among survivors of racial and ethnic minority populations.Īmong adults who were treated for cancer during childhood, late effects contribute to a high burden of morbidity. Their prevalence increases as time from cancer diagnosis elapses. Late effects are common in adults who have survived childhood cancer. Prevalence of Late Effects in Childhood Cancer Survivors Regardless of study methodology, it is important to consider selection and participation bias of the cohort studies in the context of the findings. The highest quality data typically comes from studies that report outcomes in survivors who have undergone medical assessments that provide well-characterized clinical statuses, treatment exposures, and specific late effects. High-quality data is needed to establish the occurrence of and risk profiles for late cancer treatment–related toxicity. Self-reported outcomes (provided through large-scale cohort studies).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |